DOCSLIB.ORG

Yahoo - Medgenics, Inc

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Yahoo - Medgenics, Inc Yahoo - Medgenics, Inc. Completes $7 Million Round of Financing Led by Alta Partners and Koor Corporate Venture Capital Finance Home - Yahoo! - Help [ Latest Headlines | Market Overview | News Alerts ] Wednesday June 20, 8:24 am Eastern Time Related Quotes Press Release ^DJI 10647.33 +50.66 ^IXIC 2031.24 +38.58 ^SPC 1223.14 +10.56 173.48 +5.75 ^IIX Medgenics, Inc. Completes $7 Million 706.90 +6.32 ^PSE Round of Financing Led by Alta delayed 20 mins - disclaimer Partners and Koor Corporate Venture Capital ADVERTISEMENT Additional Investors in the Round Include Alta Berkeley Venture Partners of UK MISGAV, Israel--(BW HealthWire)--June 20, 2001-- Medgenics, Inc., an early stage US/Israel biotechnology company, announced today that it has completed its Series A funding round, raising $7 million from three leading venture funds: Alta Partners (US), Koor Corporate Venture Capital (Israel) and Alta Berkeley Venture Partners (UK). Medgenics is developing a new, cost effective, long term and patient friendly way to treat a wide variety of diseases, using genetically engineered tissue to produce therapeutic proteins in the body. Through its wholly owned Israeli subsidiary, Biogenics, Ltd., Medgenics owns the exclusive license to a recently patented breakthrough for the long term delivery of therapeutic proteins, called the Biopump(tm). Based upon tissue and genetic engineering, the Biopump(tm) offers a unique platform technology using a patient's own skin, that enables the safe, long term production and delivery within the body of virtually any therapeutic protein for a wide range of applications in medicine. Without most of the drawbacks of gene therapy, the Biopump(tm) has the potential to replace http://www.medgenics.com/pr/yahoo.htm (1 of 3) [10/20/2002 9:20:51 AM] Yahoo - Medgenics, Inc. Completes $7 Million Round of Financing Led by Alta Partners and Koor Corporate Venture Capital the current protein delivery model that consists of multiple protein injections that are highly expensive, uncomfortable and often produce complications. Medgenics' lead investor in the Series A funding is Alta Partners of San Francisco, led by Senior Partner, Jean Deleage. A founder of Alta Partners, Jean Deleage has been a pioneer in the venture capital industry and was a very early investor in Genentech Inc., Chiron Corp. and Amgen, Inc. Mr. Deleage stated, ``we were fascinated to discover, within a pioneer's environment in northern Galilee, one of the most fascinating and state-of- the-art drug delivery projects of today's biopharmaceutical world, and to meet its very experienced leaders, Dr. Pearlman and Dr. Garfinkel. Needless to say that Alta made a significant investment and decided to commit the necessary time to contribute to Medgenics' success.'' G. Kirk Raab has also joined the Medgenics team as its Chairman of the Board. Mr. Raab was the former CEO of Genentech, Inc. and the past President of Abbott Pharmaceuticals, and he is the current Chairman of Oxford Glycosciences PLC and Connetics Corp. Professor Eugene Bauer, who is Stanford University's Vice President of Medical Affairs and the former Dean of Stanford's School of Medicine, also serves on the Board of Directors and is the Chairman of Medgenics' Scientific Advisory Board, which includes Dr. Alfred Alberts, former Vice President of Research & Development at Merck & Co. Einat Wilf, General Partner with Koor Corporate Venture Capital commented, ``We are very pleased to announce our investment in Medgenics; it is a testimony to our continued commitment to investing in life sciences companies with breakthrough technology and experienced management teams. Medgenics' CEO, Andrew Pearlman, is one of Israel's most experienced and successful inventors, developers and company founders in biomedical technology and instrumentation. His founding partner and Chief Scientist, Leonard Garfinkel, is one of Israel's most experienced scientists with over 25 years experience in molecular biology.'' David Needham, PhD, a Partner at Alta Berkeley Venture Partners concurred, ``Medgenics promises an elegant solution for the delivery of molecular therapies. We are very pleased to be making our first investment in Israeli technology with such exciting prospects and with such a pre-eminent group of biotech investors and entrepreneurs.'' With the Series A funding round successfully completed, Medgenics, Inc. is well positioned to develop its promising technology. Andrew Pearlman, CEO and Founder enthusiastically affirmed, ``This investment is a tribute to Medgenics' team and it's breakthrough technology for molecular therapy, and a major milestone for an early stage Israeli http://www.medgenics.com/pr/yahoo.htm (2 of 3) [10/20/2002 9:20:51 AM] Yahoo - Medgenics, Inc. Completes $7 Million Round of Financing Led by Alta Partners and Koor Corporate Venture Capital biotechnology company. We are confident that these funds will enable the company to reach compelling in- vivo proof of principle and to make major steps towards early clinical trials. Furthermore, we hope to show that the Biopump(TM)'s unique ability to quickly produce and deliver therapeutic proteins can also be used to significantly reduce the delay between the discovery of a promising new gene from the human genome and its practical clinical use to help patients.'' Contact: Medgenics, Inc. Dr. Andrew L. Pearlman, (972)-4-999-0550 [email protected] Email this story - Most-emailed articles - Most-viewed articles Related News Categories: biotech Help Copyright © 2001 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service Copyright © 2001 Business Wire. All rights reserved. All the news releases provided by Business Wire are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form. Questions or Comments? http://www.medgenics.com/pr/yahoo.htm (3 of 3) [10/20/2002 9:20:51 AM].
Load more

Recommended publications
  • Philadelphia Investment Trends Report
    Venture impact Technology investment in the Greater Philadelphia region Trends and highlights, January 2008 to June 2013 Innovation, investment and opportunity On behalf of EY, Ben Franklin Technology Partners of Southeastern Pennsylvania and the Greater Philadelphia Alliance for Capital and Technologies (PACT), we are pleased to present this review 421 companies of technology investment trends and highlights in the Greater Philadelphia region. $4.1 billion The technology investment community in the Greater Philadelphia region includes a wide variety of funding sources supporting a diverse array of companies and industry sectors. In this report, Total investment since we’ve analyzed more than a thousand investment rounds and January 2008 exits that occurred in the Philadelphia region since 2008 – including investments from venture capital fi rms (VCs), angel investors (Angels), corporate/strategic investors, seed funds, accelerators and other sources of funding. As shown in this report, 2012 reversed a post-recession slowdown in venture funding in Greater Philadelphia, and to date, 2013 has brought a welcome increase in the amount of new funds available at regional investment fi rms. These are positive signs for our region’s technology companies, as are the increasing number of exits via IPO and acquisition, which serve as further validation of the investment opportunities created by our region’s growing technology sector. We encourage you to explore this report, and we hope that it will provide useful insights into the current state of
    [Show full text]
  • Semi-Annual Market Review
    Semi-Annual Market Review HEALTH IT & HEALTH INFORMATION SERVICES JULY 2019 www.hgp.com TABLE OF CONTENTS 1 Health IT Executive Summary 3 2 Health IT Market Trends 6 3 HIT M&A (Including Buyout) 9 4 Health IT Capital Raises (Non-Buyout) 14 5 Healthcare Capital Markets 15 6 Macroeconomics 19 7 Health IT Headlines 21 8 About Healthcare Growth Partners 24 9 HGP Transaction Experience 25 10 Appendix A – M&A Highlights 28 11 Appendix B – Buyout Highlights 31 12 Appendix C – Investment Highlights 34 Copyright© 2019 Healthcare Growth Partners 2 HEALTH IT EXECUTIVE SUMMARY 1 An Accumulating Backlog of Disciplined Sellers Let’s chat about fireside chats. The term first used to describe a series of evening radio addresses given by U.S. President Franklin D. Roosevelt during the Great Depression and World War II is now investment banker speak for “soft launches” of sell-side and capital raise transactions. Every company has a price, and given a market of healthy valuations, more companies are testing the waters to find out whether they can achieve that price. That process now looks a little more informal, or how you might envision a fireside chat. Price (or valuation) discovery for a company can range from a single conversation with an individual buyer to a full-blown auction with hundreds of buyers and everything in between, including a fireside chat. Given the increasing share of informal conversations, the reality is that more companies are for sale than meets the eye. While the healthy valuations publicized and press-released are encouraging more and more companies to price shop, there is a simultaneous statistical phenomenon in perceived valuations that often goes unmentioned: survivorship bias.
    [Show full text]
  • Growthink Research 2004 Annual Healthcare Venture Capital Report
    EXECUTIVE SUMMARY & SAMPLE PAGES 2004 ANNUAL REPORT Healthcare Venture Capital Report growthink RESEARCH $5.8 Billion Invested 470 Company Profiles 525 Investor Profiles www.growthinkresearch.com growthink⏐RESEARCH Executive Summary Introduction Four hundred seventy (470) privately held biotechnology, pharmaceutical, medical device and other healthcare companies raised $5.8 billion in venture capital in 2003. These companies received over 30% of the total dollars invested, up from 26% in 2002. Investments in this sector picked up considerably in the latter half of 2003 following the successful IPOs of venture-backed companies such as Acusphere, CancerVax and Myogen. With more healthcare companies slated to go public in 2004, the industry is optimistic for an extraordinary year. Total U.S. Funding by Sector – 2003 Dollars Pct. of No. of Pct. of Average Invested Total Cos. Total Deal Size Connectivity $6,817,557,000 35.8% 576 31.0% $11,836,036 Healthcare $5,813,374,000 30.5% 470 25.3% $12,368,881 Business Software & Services $3,962,150,000 20.8% 542 29.1% $7,310,240 Other $1,438,194,000 7.6% 161 8.7% $8,932,882 E-Content & Commerce $998,950,000 5.2% 111 6.0% $8,999,550 Totals: $19,030,225,000 100.0% 1860 100.0% $10,231,304 Regions Bay Area companies led the nation in raising capital, receiving 23% of the dollars invested. CoTherix (Belmont, CA) and Corgentech (South San Francisco, CA) led the region, which was home to 96 healthcare ventures that raised $1.4 billion. CoTherix, a biopharmaceutical company that develops and commercializes therapeutics for life-threatening diseases, completed a $55 million Series C round.
    [Show full text]
  • Clear Route to Phase Iib
    REPRINT FROM MARCH 24, 2008 BioCentury ® THE BERNSTEIN REPORT ON BIOBUSINESS Article Reprint Page 1 of 9 Ebb & Flow Focus Clear route to Phase IIb By Mike Ward investment with the potential to follow on up to a total of $30- Senior Editor $40 million per company.” Although big series A rounds have become increasingly Indeed, the average size of the 10 most recent rounds Phase4 commonplace, the recent deal for Albireo AB, expected to Ventures has participated in is a touch over $50 million. This is reach $40 million, reflects business as usual for Nomura more than two and a half times the average biotech venture Phase4 Ventures. The London firm has taken an aggres- round over the same period. sive approach to investing its parent’s money in biotech, Phase4 has participated in three series A rounds in the past characterized by large financing rounds geared to providing three years in which the syndicates committed a total of $162 a clear route to Phase IIb data, underpinned by international million to the three companies. syndication. The firm focuses primarily on investment in clinical stage Phase4’s story is one of increasing scale, with rounds companies and as a result has a portfolio that is heavily biased mounting in size from 1999 until the VC toward the U.S. Over 75% of the compa- hit its stride in 2004. Since then, the firm nies Phase4 invests in are in Phase I or has usually taken the lead in $1.3 billion “You need to bring enough II, with an average holding time of about worth of venture rounds.
    [Show full text]
  • Final Rule: Exemptions for Advisers to Venture Capital Funds
    SECURITIES AND EXCHANGE COMMISSION 17 CFR Part 275 Release No. IA-3222; File No. S7-37-10 RIN 3235-AK81 Exemptions for Advisers to Venture Capital Funds, Private Fund Advisers With Less Than $150 Million in Assets Under Management, and Foreign Private Advisers AGENCY: Securities and Exchange Commission. ACTION: Final rule. SUMMARY: The Securities and Exchange Commission (the ―Commission‖) is adopting rules to implement new exemptions from the registration requirements of the Investment Advisers Act of 1940 for advisers to certain privately offered investment funds; these exemptions were enacted as part of the Dodd-Frank Wall Street Reform and Consumer Protection Act (the ―Dodd- Frank Act‖). As required by Title IV of the Dodd-Frank Act – the Private Fund Investment Advisers Registration Act of 2010 – the new rules define ―venture capital fund‖ and provide an exemption from registration for advisers with less than $150 million in private fund assets under management in the United States. The new rules also clarify the meaning of certain terms included in a new exemption from registration for ―foreign private advisers.‖ DATES: Effective Date: July 21, 2011. FOR FURTHER INFORMATION CONTACT: Brian McLaughlin Johnson, Tram N. Nguyen or David A. Vaughan, at (202) 551-6787 or <[email protected]>, Division of Investment Management, U.S. Securities and Exchange Commission, 100 F Street, NE, Washington, DC 20549-8549. SUPPLEMENTARY INFORMATION: The Commission is adopting rules 203(l)-1, 203(m)-1 and 202(a)(30)-1 (17 CFR 275.203(l)-1, 275.203(m)-1 and 275.202(a)(30)-1) under the - 2 - Investment Advisers Act of 1940 (15 U.S.C.
    [Show full text]
  • Private Equity Analyst
    PRIVATE EQUITY ANALYST NOVEMBER 2020 Women to Private Equity’s Top Female Talent of Today and Tomorrow p. 7 10 VCs Grooming Game-Changing Startups p. 13 Watch LP Cycles Ad HFA+PEA-Ltr DR080420.pdf 1 8/4/20 5:43 PM Private equity investing has its cycles. Work with a secondary manager who’s C experienced them all. M Y CM MY As leaders of the secondary market, the Lexington Partners team CY draws on more than 400 years of private equity experience. CMY Through all types of business cycles, we have completed over K 500 secondary transactions, acquiring more than 3,000 interests managed by over 750 sponsors with a total value in excess of $53 billion. Our team has excelled at providing customized alternative investment solutions to banks, financial institutions, pension funds, sovereign wealth funds, endowments, family offices, and other fiduciaries seeking to reposition their private investment portfolios. If you have an interest in the secondary market, our experience is second to none. To make an inquiry, please send an email to [email protected] or call us at one of our offices. Innovative Directions in Alternative Investing New York • Boston • Menlo Park • London • Hong Kong • Santiago • Luxembourg www.lexingtonpartners.com Includes information regarding six funds managed by Lexington’s predecessor formed during the period 1990 to 1995. This information is provided for informational purposes only and is not an offer to sell or solicitation of offers to purchase any security. Private Equity Analyst November 2020 contents Volume XXX, Issue 11 Fund News u The Roundup Comment Clayton Dubilier Collects About $14B for Latest Buyout Fund 26 H.I.G.
    [Show full text]
  • CED 2014 Innovators Report Hires
    INNOVATORS REPORT 2013 Trends in North Carolina Entrepreneurship 2013 IPO WATCH 226 NATIONAL 9 STATEWIDE 1. Aerie Pharmaceuticals 26 2. ChannelAdvisor SOUTHEAST 3. Chimerix 4. Heat Biologics 5. LipoScience 6. Ply Gem Holdings 7. Quintiles 8. Regado Biosciences 9. Stock Building Supply REPORT SOURCES: CED, National Venture Capital Association (NVCA), North Carolina Biotechnology Center, Ernst & Young, PricewaterhouseCoopers, SBIR.gov The Innovators Report is made possible by generous gifts to the CED Annual Fund. Thank you to our many supporters! For more information on how to contribute, please visit www.cednc.org/donate. MAJOR MERGERS & NC EVENTS ACQUISITIONS* DSM Pharmaceuticals Patheon $2.6 billion Santarus Salix Pharmaceuticals $2.6 billion COMPANY PRA International Kolberg, Kravis & Roberts $1.3 billion MILESTONES Solstas Lab Partners Quest Diagnostics $570 million Medicago Mitsubishi Tanabe Pharma $357 million Recognized as Advanced Liquid Logic Illumina $96 million 50 million Named Cracks a “Disrupter” sponsored 2013 Top 50 for the wireless Exam Design Pearson VUE app installs Fierce in Digital industry by Top 15 Health Entrepreneur Magazine Geomagic 3D Systems GrassRoots Biotechnology Monsanto Novella Clinical Quintiles Secure Enterprise Computing Agio Technology Axial Republic Appia Scioderm Exchange Wireless Tekelec Oracle ACQUIRED ACQUIRED BY *Partial listing DEALS & PARTNERSHIPS Signs up Yahoo! Sports, Bloomberg, CBS and Gannett $70 million deal with Toyama Chemical Company and a $58 million BARDA contact CHATHAM THERAPEUTICS
    [Show full text]
  • Life Sciences Venture Equity Market Review: the Evolving Role of Crossover Investors
    Life Sciences Venture Equity Market Review: The Evolving Role of Crossover Investors June 2021 Securities offered in the United States are offered through Torreya Capital LLC, Member FINRA/SIPC. In Europe such services are offered through Torreya Partners (Europe) LLP, which is authorized and regulated by the UK Financial Conduct Authority. The Market for Equity Privates in Life Sciences TORREYA | PRIVATE LIFE SCIENCES VENTURE FINANCING MARKET REVIEW – JUNE 2021 2 Total Private Venture Financing Volume: 2000-2021 H1 Given volumes in the first half of this year, there is little doubt that 2021 will shape up to be the most active year in history for private financing activity in the life sciences sector. Total Volume of Private Biopharma, Diagnostics and Tools 50000 Financing Rounds by Year Jan 2000 - June 2021 600 (deals over $25mm, excluding medical devices, worldwide) 45000 523 500 40000 35000 373 400 356 30000 334 25000 300 20000 224 226 Transaction Transaction Count 184 200 15000 145 138 121 122 111 10000 109 88 97 96 81 72 100 Aggregate Aggregate Dollar Volume of Private Financings ($mm) 55 5000 40 35 23 0 0 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2017 2018 2019 2020 2021 H1 Transaction Count Dollar Volume ($mm) Source: Torreya analysis and records, CapitalIQ and Crunchbase TORREYA | PRIVATE LIFE SCIENCES VENTURE FINANCING MARKET REVIEW – JUNE 2021 3 Fresh Venture Capital Flowing into Life Science Sector We are on track to see record amount raised in life science venture capital in 2021.
    [Show full text]
  • Silicon Valley London Woodside Capital Partners (WCP)
    Silicon Valley London Woodside Capital Partners (WCP) proudly releases the inaugural healthcare report “State of Digital Health”. In 2016, healthcare cost in the US was $3.3 Trillion – 17.9% of GDP, passing $10,000 per capita mark for the first time ever. According to CMS, by 2026, the figure is projected to grow to $5.7 Trillion – 19.8% of GDP. The answer to curbing and reversing the trend with respect to healthcare costs lies in large part to the movement towards Digital Health, or ‘Health Tech’. The proliferation of devices and applications across the healthcare spectrum has led to a data tsunami – the “what”. Machine Learning, Artificial Intelligence and overall Big Data analytics are leading to real-time actionable insights – the “so what”. We have entered the realm of the Internet of Medical Things (IoMT), with ubiquitous connectivity and measurement of everything from our vitals and nutrition to physical activity and medical compliance. We are just starting to leverage that data in a meaningful way and seeing early impact on health and well-being. In 2017, venture investments in Digital Health startups exceeded $6 Billion for the first time, and the trend seems to be accelerating with $1.6 Billion invested in Q1, 2018. The juxtaposition of rising healthcare costs and increased Digital Health investments is not all that surprising. Advances in underlying real-time analytics and potential of leading edge innovations around genomics are turning the perceived fiction of personalized medicine into a real possibility. Foundational disruptions such as Blockchain, while relatively nascent, are creating excitement (and some anxiety) around secure, immutable data sharing across silos – with healthcare as the ideal use case.
    [Show full text]
  • Biotechnology Startups Research Report
    GLOBAL BUSINESS CONFIDENCE REPORT 4th Qtr. 2019 B IOTECH NOLOGY STARTUPS RESEARCH REPORT 4th Quarter 2019 www.tradecouncil.org www.qibcertification.org International Trade Council www.tradecouncil.org www.goglobalawards.org Page 1 MARKET OVERVIEW REPORT FOR ENTERPRISE ESTONIA Table of Contents Overview ........................................................................................................................................................................... 3 Industry Definition .......................................................................................................................................................................................... 3 Sectoral Definitions ........................................................................................................................................................................................ 3 Main Activities .................................................................................................................................................................................................. 4 Associated Industries ..................................................................................................................................................................................... 4 Industry at a Glance ......................................................................................................................................................... 5 Industry Overview ..........................................................................................................................................................................................
    [Show full text]
  • REPORT 2015 Vol. 6
    REPORT 2015 vol. 6 Forward-thinking articles from our global network of innovation ecosystem experts KFR Staff KF Board of Directors Publisher Brian Dovey, Chairman Kauffman Fellows Press Domain Associates Executive Editor Tom Baruch Phil Wickham Formation 8 Managing Editor Jason Green Anna F.Doherty Emergence Capital Partners Associate Editor Karen Kerr Leslie F. Peters Agile Equities, LLC Production and Design Audrey MacLean Anna F. Doherty Stanford University Leslie F. Peters Susan Mason Printer Aligned Partners Almaden Press www.almadenpress.com Jenny Rooke Copyright Fidelity Biosciences © 2015 Kauffman Fellows. All rights reserved. Christian Weddell Under no circumstances shall any of the information provided herein be construed as investment advice of any kind. Copan About the Editor Phil Wickham Anna F. Doherty is an accomplished editor and writing Kauffman Fellows coach with a unique collaborative focus in her work. She has 20 years of editing experience on three continents in a variety of business industries. Through her firm, Together Editing & Design, she has offered a full suite of writing, design, and publishing services to Kauffman Fellows since 2009. Leslie F. Peters is the Lead Designer on the TE&D team. www.togetherediting.com www.kauffmanfellows.org Town & Country Village • 855 El Camino Real, Suite 12 • Palo Alto, CA 94301 Phone: 650-561-7450 • Fax: 650-561-7451 Venturing into the Industry: Lessons Learned from a VCpreneur Ahmad Takatkah Class 17 My life has been swinging between in Empretec,2 an international entrepreneurship and venture capital for more entrepreneurship training program than ten years now. In each cycle, I get closer that is managed by the United Nations and to my goal, even as I refine my goals further.
    [Show full text]
  • Jean Deleage
    PROFILE Jean Deleage A hands-off philosophy based on investing in people has served growth factor inhibitor Macugen (pegaptanib), for treating wet macular Jean Deleage well over almost 35 years of venture capital investing degeneration in the eye, acquired from biotech company Foster City, in the life sciences. He reflects on biotech investment trends. California-based anti-infective biotech Gilead Sciences), and Eyetech was able to value Macugen mainly because of its founders’ expertise in the development of drugs to treat diseases of the eye. From his initial experience watching the creation of Genentech to having Hurwitz commends Deleage as a risk taker and for being ahead of the his own life sciences venture capital (VC) company, Jean Deleage has curve. A year-and-a-half ago Deleage complained that the typical ven- enjoyed a good life as a biotech investor. Deleage began his VC career in ture capitalist process of staying in touch with thought leaders, finding 1971 in Paris, when he became involved in a task force looking at inno- the next star in molecular biology and funding that person’s ideas was “a vation in France. “We determined that we needed venture capital,” he lazy approach” to company building. “Instead of going to UCSF to find explains, and at the time, the only place venture capital had established the next Michael Bishop,” he said then, “we go to the hospital across the itself was the United States. With little financial experience, Deleage street and build companies around clinical programs.” started Sofinnova at the end of 1971, as a small fund for US investment, Yet although that was the philosophy behind the creation of Alta’s operating in France.
    [Show full text]